Abstract
The high mortality of non-small cell lung cancer (NSCLC) is mainly because the cancer has progressed to a more advanced stage before diagnosis. If NSCLC can be diagnosed at early stages, especially stage 0 or I, the overall survival rate will be largely improved by definitive treatment such as lobectomy. We herein validated two novel circulating serum ExmiRs as diagnostic biomarkers for early-stage NSCLC to fulfill the unmet medical need. Considering the number of specimens in this study, circulating serum exosomal miR-20b-5p and miR-3187-5p are putative NSCLC biomarkers, which need to be further investigated in a larger randomized controlled clinical trial.
Keywords:
Diagnostic biomarkers; circulation; exosomes; miRNAs; non-small cell lung cancer.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Area Under Curve
-
Biomarkers, Tumor / blood*
-
Biomarkers, Tumor / genetics
-
Carcinoma, Non-Small-Cell Lung / blood*
-
Carcinoma, Non-Small-Cell Lung / diagnosis
-
Carcinoma, Non-Small-Cell Lung / genetics*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Circulating MicroRNA / blood*
-
Circulating MicroRNA / genetics
-
Exosomes / metabolism*
-
Exosomes / ultrastructure
-
Female
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Lung Neoplasms / blood
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / genetics*
-
Lung Neoplasms / pathology
-
Male
-
MicroRNAs / blood*
-
MicroRNAs / genetics
-
Middle Aged
-
Neoplasm Staging
Substances
-
Biomarkers, Tumor
-
Circulating MicroRNA
-
MIRN20a microRNA, human
-
MIRN3187 microRNA, human
-
MicroRNAs